The neuroimmune axis of Alzheimer's disease
Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder with
multifaceted neuropathological features, including β-amyloid plaques, neurofibrillary …
multifaceted neuropathological features, including β-amyloid plaques, neurofibrillary …
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?
Alzheimer disease (AD) is the most common form of neurodegenerative disease, estimated
to contribute 60–70% of all cases of dementia worldwide. According to the prevailing …
to contribute 60–70% of all cases of dementia worldwide. According to the prevailing …
Neuroinflammation in Alzheimer's disease: current progress in molecular signaling and therapeutics
Alzheimer's disease, a neurodegenerative disease with amyloid beta accumulation as a
major hallmark, has become a dire global health concern as there is a lack of clear …
major hallmark, has become a dire global health concern as there is a lack of clear …
Microglia in the neuroinflammatory pathogenesis of Alzheimer's disease and related therapeutic targets
Y Cai, J Liu, B Wang, M Sun, H Yang - Frontiers in immunology, 2022 - frontiersin.org
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease worldwide,
characterized by progressive neuron degeneration or loss due to excessive accumulation of …
characterized by progressive neuron degeneration or loss due to excessive accumulation of …
Inflammation in CNS neurodegenerative diseases
J Stephenson, E Nutma, P van der Valk, S Amor - Immunology, 2018 - Wiley Online Library
Neurodegenerative diseases, the leading cause of morbidity and disability, are gaining
increased attention as they impose a considerable socioeconomic impact, due in part to the …
increased attention as they impose a considerable socioeconomic impact, due in part to the …
Targeting neuroinflammation in Alzheimer's disease: From mechanisms to clinical applications
ZZ Si, CJ Zou, X Mei, XF Li, H Luo, Y Shen… - Neural regeneration …, 2023 - journals.lww.com
Alzheimer's disease is characterized by sustained neuroinflammation leading to memory
loss and cognitive decline. The past decade has witnessed tremendous efforts in …
loss and cognitive decline. The past decade has witnessed tremendous efforts in …
[HTML][HTML] Irisin reduces amyloid-β by inducing the release of neprilysin from astrocytes following downregulation of ERK-STAT3 signaling
A pathological hallmark of Alzheimer's disease (AD) is the deposition of amyloid-β (Aβ)
protein in the brain. Physical exercise has been shown to reduce Aβ burden in various AD …
protein in the brain. Physical exercise has been shown to reduce Aβ burden in various AD …
[HTML][HTML] Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?
Alzheimer's Disease (AD) is a chronic neurodegenerative disorder and the most common
type of dementia (60–80% of cases). In 2016, nearly 44 million people were affected by AD …
type of dementia (60–80% of cases). In 2016, nearly 44 million people were affected by AD …
Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model
Alzheimer disease (AD) is the most common neurodegenerative disease. An imbalance
between the production and clearance of Aβ (amyloid beta) is considered to be actively …
between the production and clearance of Aβ (amyloid beta) is considered to be actively …
Alzheimer's disease: Novel targets and investigational drugs for disease modification
JL Cummings, AML Osse, JW Kinney - Drugs, 2023 - Springer
Novel agents addressing non-amyloid, non-tau targets in Alzheimer's Disease (AD)
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …
comprise 70% of the AD drug development pipeline of agents currently in clinical trials. Most …